You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 9, 2024

Investigational Drug Information for Intepirdine


✉ Email this page to a colleague

« Back to Dashboard


What is the drug development status for Intepirdine?

Intepirdine is an investigational drug.

There have been 5 clinical trials for Intepirdine. The most recent clinical trial was a Phase 3 trial, which was initiated on April 26th 2016.

The most common disease conditions in clinical trials are Alzheimer Disease, Lewy Body Disease, and Dementia. The leading clinical trial sponsors are Axovant Sciences Ltd. and [disabled in preview].

There are twelve US patents protecting this investigational drug and one hundred and eighty international patents.

Recent Clinical Trials for Intepirdine
TitleSponsorPhase
Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With DementiaAxovant Sciences Ltd.Phase 2
Long-Term Extension Study of Intepirdine (RVT-101) in Subjects With Dementia With Lewy Bodies: HEADWAY-DLB ExtensionAxovant Sciences Ltd.Phase 2/Phase 3
12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET ExtensionAxovant Sciences Ltd.Phase 3

See all Intepirdine clinical trials

Clinical Trial Summary for Intepirdine

Top disease conditions for Intepirdine
Top clinical trial sponsors for Intepirdine

See all Intepirdine clinical trials

US Patents for Intepirdine

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Intepirdine ⤷  Sign Up Controlled release dosage form TRIASTEK, INC. (Nanjing, CN) ⤷  Sign Up
Intepirdine ⤷  Sign Up Application of 5-HT6 receptor antagonists for the alleviation of cognitive deficits of down syndrome THE UNIVERSITY OF UTAH RESEARCH FOUNDATION (Salt Lake City, UT) ⤷  Sign Up
Intepirdine ⤷  Sign Up Methods of treating dementia and pharmaceutical compositions thereof H. LUNDBECK A/S (Valby, DK) ⤷  Sign Up
Intepirdine ⤷  Sign Up 5-HT6 receptor antagonists for use in the treatment of Alzheimer's disease with apathy as comorbidity H. Lundbeck A/S (Valby, DK) ⤷  Sign Up
Intepirdine ⤷  Sign Up Combinations comprising substituted imidazo[1,5-a]pyrazinones as PDE1 inhibitors H. Lundbeck A/S (Valby, DK) ⤷  Sign Up
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Intepirdine

Drugname Country Document Number Estimated Expiration Related US Patent
Intepirdine Australia AU2017261372 2036-05-05 ⤷  Sign Up
Intepirdine Canada CA3023278 2036-05-05 ⤷  Sign Up
Intepirdine China CN107847398 2036-05-05 ⤷  Sign Up
Intepirdine European Patent Office EP3452003 2036-05-05 ⤷  Sign Up
Intepirdine European Patent Office EP3981392 2036-05-05 ⤷  Sign Up
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.